arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Assertio Holdings, Inc.

ASRT
Price unavailable
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
8 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
29
Health
Poor
Bearish
auto_awesome

Analytical Summary

Assertio Holdings, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap
Dividend Yield
Revenue Growth -5.0%
Op. Margin -18.1%
ROIC -16.4%
FCF / Share $-4.40
Trailing P/E
Price / Book
FCF Yield
Debt / Equity 0.42
info Valuation on last close.

8-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$118.71M
↓ -5.0%
Net Income Profit after all expenses
$-30.38M
↓ -40.7%
Operating Margin Operating profit as % of sales
-18.1%
↑ +7.4% 11th
FCF / Share Free cash flow per share
$-4.40
↓ -205.9%
Long-Term Debt Long-term obligations
$39.12M
↑ +0.8%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
9
Returns
22
Financial Health
44
Cash Quality
62

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 30 quarters